Human papillomavirus vaccination of females in a large health claims database in the United States, 2006-2012
- PMID: 25797632
- PMCID: PMC5905697
- DOI: 10.1016/j.jadohealth.2015.01.004
Human papillomavirus vaccination of females in a large health claims database in the United States, 2006-2012
Abstract
Purpose: Information on vaccine utilization from a variety of sources is useful to give a status of the vaccine program and define opportunities to improve uptake. We evaluated MarketScan Commercial Claims and Encounters database on human papillomavirus (HPV) vaccine initiation and completion of all three doses among girls/women from 2006 to 2012.
Methods: Data were obtained from the 2006-2012 MarketScan Commercial Claims and Encounters database. The study population included female enrollees aged 11-26 years who were continuously enrolled in the same private insurance plan from 2006 to 2012 (n = 407,371). We evaluated overall and yearly vaccine initiation and completion, demographic characteristics associated with vaccine initiation, clinical visits in which vaccine was given, and missed opportunities for vaccination.
Results: By the end of 2012, 36.9% of females aged 11-26 years had received at least one HPV vaccine dose. Vaccination coverage was highest among females aged 17-18 years (49.3%) and aged 15-16 years (43.1%) and lowest among females aged 11-12 years (16.8%). Between 2007 and 2012, 96.1% of the 246,192 unvaccinated females had at least one missed opportunity (a heath care visit without HPV vaccine administered).
Conclusions: Over a 6 year period, HPV vaccine initiation was lowest in the girls aged 11-12 years. Importantly, most (96.1%) unvaccinated females had at least one missed vaccination opportunity, and providers and health systems should focus efforts on using existing visits for vaccination.
Keywords: Administrative data; HPV vaccine; Missed opportunities for vaccination; Vaccine coverage.
Published by Elsevier Inc.
Conflict of interest statement
Figures

References
-
- Center for Disease Control. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP) MMWR Morb Mortal Wkly Rep. 2010;59:626–9. - PubMed
-
- Center for Disease Control. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine, recommendations of the Advisory Committee for Immunization Practices (ACIP) MMWR Recomm Rep. 2007;56:1–24. - PubMed
-
- Dunne EF, Markowitz LE, Chesson H, et al. Recommendations on the use of quadrivalent human papillomavirus vaccine in Males—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705–8. - PubMed
-
- Center for Disease Control. National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117–23. - PubMed